We are live on ! Find out more
RIGL icon

Rigel Pharmaceuticals
RIGL

112 hedge funds and large institutions have $176M invested in Rigel Pharmaceuticals in 2023 Q4 according to their latest regulatory filings, with 16 funds opening new positions, 38 increasing their positions, 28 reducing their positions, and 10 closing their positions.

New
Increased
Maintained
Reduced
Closed

1,704% more call options, than puts

Call options by funds: $1.39M | Put options by funds: $77K

60% more first-time investments, than exits

New positions opened: 16 | Existing positions closed: 10

53% more capital invested

Capital invested by funds: $115M → $176M (+$61.3M)

36% more repeat investments, than reductions

Existing positions increased: 38 | Existing positions reduced: 28

6% more funds holding

Funds holding: 106 → 112 (+6)

0.85% more ownership

Funds ownership: 6.09% → 6.94% (+0.85%)

Holders
112
Holders Change
+6
Holders Change %
+5.66%
% of All Funds
1.63%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
16
Increased
38
Reduced
28
Closed
10
Calls
$1.39M
Puts
$77K
Net Calls
+$1.31M
Net Calls Change
+$515K

Top Buyers

1
Morgan Stanley
Morgan Stanley
New York
+$22.4M
2
BlackRock
BlackRock
New York
+$802K
3
GCP
GSA Capital Partners
United Kingdom
+$466K
4
Squarepoint
Squarepoint
New York
+$331K
5
ZIM
Zacks Investment Management
Illinois
+$309K

Top Sellers

1
SCM
Soleus Capital Management
Connecticut
-$5.48M
2
Millennium Management
Millennium Management
New York
-$2.39M
3
Assenagon Asset Management
Assenagon Asset Management
Luxembourg
-$796K
4
Jacobs Levy Equity Management
Jacobs Levy Equity Management
New Jersey
-$700K
5
Two Sigma Advisers
Two Sigma Advisers
New York
-$381K
Name Holding Trade Value Shares
Change 		Change in
Stake
Morgan Stanley
1
Morgan Stanley
New York
$41.9M +$22.4M +2,192,775 +314%
AC
2
Armistice Capital
New York
$24.8M -$36.8K -3,600 -0.2%
BlackRock
3
BlackRock
New York
$22M +$802K +78,458 +5%
SCM
4
Soleus Capital Management
Connecticut
$13.7M -$5.48M -536,044 -36%
Vanguard Group
5
Vanguard Group
Pennsylvania
$13M +$87.4K +8,547 +1%
Acadian Asset Management
6
Acadian Asset Management
Massachusetts
$6.7M -$39.9K -3,898 -0.8%
Geode Capital Management
7
Geode Capital Management
Massachusetts
$5.36M +$149K +14,560 +4%
State Street
8
State Street
Massachusetts
$5.19M +$78.1K +7,639 +2%
Jacobs Levy Equity Management
9
Jacobs Levy Equity Management
New Jersey
$3.89M -$700K -68,486 -20%
N
10
Nuveen
North Carolina
$3.58M +$6.79K +664 +0.3%
VOYA Investment Management
11
VOYA Investment Management
Georgia
$3.03M +$36.7K +3,592 +2%
Assenagon Asset Management
12
Assenagon Asset Management
Luxembourg
$2.89M -$796K -77,844 -28%
CM
13
CM Management
Florida
$2.46M +$205K +20,000 +13%
Macquarie Group
14
Macquarie Group
Australia
$2.32M – – –
Northern Trust
15
Northern Trust
Illinois
$2.24M +$24.5K +2,397 +2%
GCP
16
GSA Capital Partners
United Kingdom
$2.07M +$466K +45,560 +47%
Renaissance Technologies
17
Renaissance Technologies
New York
$1.91M +$191K +18,640 +16%
SFM
18
Sphera Funds Management
Israel
$1.78M – – –
UOC
19
UBS O'Connor
Illinois
$1.3M -$258K -25,243 -22%
Millennium Management
20
Millennium Management
New York
$1.12M -$2.39M -233,627 -75%
Charles Schwab
21
Charles Schwab
California
$1.08M -$123K -12,059 -14%
BCM
22
Bridgeway Capital Management
Texas
$972K +$77.9K +7,620 +13%
Two Sigma Advisers
23
Two Sigma Advisers
New York
$955K -$381K -37,269 -36%
Connor, Clark & Lunn Investment Management (CC&L)
24
Connor, Clark & Lunn Investment Management (CC&L)
British Columbia, Canada
$854K -$2.68K -262 -0.4%
Bank of New York Mellon
25
Bank of New York Mellon
New York
$821K +$8.07K +789 +1%
1
2 3 4 5

RIGL Hedge Fund Activity: Q4 2023 in Review

112 of the 6,859 institutional investors tracked by Wall St. Rank reported a position in Rigel Pharmaceuticals (RIGL) for Q4 2023, worth a combined $176M — up 53% from $115M a quarter earlier.

Buyers outnumbered sellers: 16 funds opened new RIGL positions and 10 closed out — a net gain of 6 holders — while 38 added to existing stakes and 28 trimmed.

The largest buyer was Morgan Stanley, adding an estimated $22.4M. The largest seller was Soleus Capital Management, cutting an estimated $5.48M.

  • 112 institutional investors held Rigel Pharmaceuticals (RIGL) as of Q4 2023, up from 106 in Q3 2023.
  • Funds reported $176M of Rigel Pharmaceuticals stock for Q4 2023, up 53% quarter-over-quarter.
  • 16 funds opened new Rigel Pharmaceuticals positions in Q4 2023 and 10 closed out, a net change of +6 holders.
  • The largest Rigel Pharmaceuticals buyer in Q4 2023 was Morgan Stanley, an estimated $22.4M added.
  • The largest Rigel Pharmaceuticals seller in Q4 2023 was Soleus Capital Management, an estimated $5.48M sold.

Based on aggregated 13F filings for Q4 2023.